Optimizing Endocrine Therapy for Breast Cancer

Restricted access

Endocrine therapy has significantly improved outcomes for patients with early- and advanced-stage hormone-receptor (HR)–positive breast cancer. Despite the success of adjuvant endocrine therapy, some patients with early-stage disease will experience relapse. Additionally, all patients with advanced disease will eventually experience disease progression on endocrine therapy due to resistance. Improved understanding of the mechanisms associated with resistance to endocrine agents has recently led to the approval of new therapeutics. Multiple questions remain unanswered, including the optimal duration of adjuvant therapy, the role of ovarian ablation in early-stage breast cancer in premenopausal women, and how to best incorporate targeted agents with endocrine therapy in the metastatic setting. This article reviews the optimization of endocrine therapy in patients with HR-positive breast cancer, focusing on these controversial areas.

Correspondence: Ruth M. O'Regan, MD, University of Wisconsin, 600 Highland Avenue, K4/542 CSC, Madison, WI 53792. E-mail: roregan@medicine.wisc.edu
  • 1.

    AndersonWFChatterjeeNErshlerWBBrawleyOW. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat2002;76:2736.

    • Search Google Scholar
    • Export Citation
  • 2.

    De LaurentiisMArpinoGMassarelliE. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res2005;11:47414748.

    • Search Google Scholar
    • Export Citation
  • 3.

    CristofanilliMValeroVMangalikA. Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clin Cancer Res2010;16:19041914.

    • Search Google Scholar
    • Export Citation
  • 4.

    TrainaTARugoHSCaravelliJF. Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer. J Clin Oncol2010;28:628633.

    • Search Google Scholar
    • Export Citation
  • 5.

    KaklamaniVGCianfroccaMCicconeJ. Increased HER2/neu expression in recurrent hormone receptor-positive breast cancer. Biomarkers2010;15:191193.

    • Search Google Scholar
    • Export Citation
  • 6.

    SorlieTPerouCMTibshiraniR. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A2001;98:1086910874.

    • Search Google Scholar
    • Export Citation
  • 7.

    PaikSShakSTangG. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med2004;351:28172826.

    • Search Google Scholar
    • Export Citation
  • 8.

    van ‘t VeerLJDaiHvan de VijverMJ. Gene expression profiling predicts clinical outcome of breast cancer. Nature2002;415:530536.

  • 9.

    GradisharWJAndersonBOBalassanianR. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 2 2015. Available at: NCCN.org. Accessed July 2 2015.

    • Search Google Scholar
    • Export Citation
  • 10.

    PuhallaSBrufskyADavidsonN. Adjuvant endocrine therapy for premenopausal women with breast cancer. Breast2009;18(Suppl 3):S122130.

  • 11.

    PaganiOReganMMWalleyBA. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med2014;371:107118.

  • 12.

    GnantMMlineritschBStoegerH. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol2011;12:631641.

    • Search Google Scholar
    • Export Citation
  • 13.

    SantenRJHarveyHA. Use of aromatase inhibitors in breast carcinoma. Endocr Relat Cancer1999;6:7592.

  • 14.

    ForbesJFCuzickJBuzdarA. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol2008;9:4553.

    • Search Google Scholar
    • Export Citation
  • 15.

    ReganMMNevenPGiobbie-HurderA. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up. Lancet Oncol2011;12:11011108.

    • Search Google Scholar
    • Export Citation
  • 16.

    BoccardoFRubagottiAGuglielminiP. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann Oncol2006;17(Suppl 7):vii1014.

    • Search Google Scholar
    • Export Citation
  • 17.

    CoombesRCHallEGibsonLJ. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med2004;350:10811092.

    • Search Google Scholar
    • Export Citation
  • 18.

    JakeszRJonatWGnantM. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet2005;366:455462.

    • Search Google Scholar
    • Export Citation
  • 19.

    BlissJMKilburnLSColemanRE. Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study. J Clin Oncol2012;30:709717.

    • Search Google Scholar
    • Export Citation
  • 20.

    van de VeldeCJReaDSeynaeveC. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet2011;377:321331.

    • Search Google Scholar
    • Export Citation
  • 21.

    FisherBDignamJBryantJWolmarkN. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst2001;93:684690.

    • Search Google Scholar
    • Export Citation
  • 22.

    JakeszRGreilRGnantM. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst2007;99:18451853.

    • Search Google Scholar
    • Export Citation
  • 23.

    MamounasEPJeongJHWickerhamDL. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial. J Clin Oncol2008;26:19651971.

    • Search Google Scholar
    • Export Citation
  • 24.

    GossPEIngleJNMartinoS. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med2003;349:17931802.

    • Search Google Scholar
    • Export Citation
  • 25.

    GossPEIngleJNMartinoS. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. J Clin Oncol2007;25:20062011.

    • Search Google Scholar
    • Export Citation
  • 26.

    DaviesCPanHGodwinJ. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet2013;381:805816.

    • Search Google Scholar
    • Export Citation
  • 27.

    GrayRReaDHandleyK. aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer [abstract]. J Clin Oncol2013;31(Suppl):Abstract 5.

    • Search Google Scholar
    • Export Citation
  • 28.

    SorlieTTibshiraniRParkerJ. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003;100:84188423.

    • Search Google Scholar
    • Export Citation
  • 29.

    SestakICuzickJDowsettM. Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of 2485 patients from the ABCSG-8 and transATAC studies using the PAM50 risk of recurrence (ROR) score [abstract]. Cancer Res2013;73(Suppls):Abstract S6-04.

    • Search Google Scholar
    • Export Citation
  • 30.

    SgroiDCSestakICuzickJ. Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncol2013;14:10671076.

    • Search Google Scholar
    • Export Citation
  • 31.

    SgroiDCCarneyEZarrellaE. Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker. J Natl Cancer Inst2013;105:10361042.

    • Search Google Scholar
    • Export Citation
  • 32.

    FilipitsMNielsenTORudasM. The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer. Clin Cancer Res2014;20:12981305.

    • Search Google Scholar
    • Export Citation
  • 33.

    DubskyPBraseJCJakeszR. The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients. Br J Cancer2013;109:29592964.

    • Search Google Scholar
    • Export Citation
  • 34.

    JinHTuDZhaoN. Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover. J Clin Oncol2012;30:718721.

    • Search Google Scholar
    • Export Citation
  • 35.

    BuzdarADoumaJDavidsonN. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol2001;19:33573366.

    • Search Google Scholar
    • Export Citation
  • 36.

    BuzdarAUJonatWHowellA. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer1998;83:11421152.

    • Search Google Scholar
    • Export Citation
  • 37.

    KaufmannMBajettaEDirixLY. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol2000;18:13991411.

    • Search Google Scholar
    • Export Citation
  • 38.

    CarliniPBriaEGiannarelliD. New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials. Cancer2005;104:13351342.

    • Search Google Scholar
    • Export Citation
  • 39.

    MouridsenHGershanovichMSunY. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol2003;21:21012109.

    • Search Google Scholar
    • Export Citation
  • 40.

    MouridsenHGershanovichMSunY. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol2001;19:25962606.

    • Search Google Scholar
    • Export Citation
  • 41.

    NabholtzJMBonneterreJBuzdarA. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. Eur J Cancer2003;39:16841689.

    • Search Google Scholar
    • Export Citation
  • 42.

    Milla-SantosAMillaLPortellaJ. Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study. Am J Clin Oncol2003;26:317322.

    • Search Google Scholar
    • Export Citation
  • 43.

    OsborneCKPippenJJonesSE. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol2002;20:33863395.

    • Search Google Scholar
    • Export Citation
  • 44.

    HowellAPippenJElledgeRM. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials. Cancer2005;104:236239.

    • Search Google Scholar
    • Export Citation
  • 45.

    HowellARobertsonJFQuaresma AlbanoJ. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol2002;20:33963403.

    • Search Google Scholar
    • Export Citation
  • 46.

    HowellARobertsonJFAbramP. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol2004;22:16051613.

    • Search Google Scholar
    • Export Citation
  • 47.

    RobertsonJFEriksteinBOsborneKC. Pharmacokinetic profile of intramuscular fulvestrant in advanced breast cancer. Clin Pharmacokinet2004;43:529538.

    • Search Google Scholar
    • Export Citation
  • 48.

    Di LeoAJerusalemGPetruzelkaL. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol2010;28:45944600.

    • Search Google Scholar
    • Export Citation
  • 49.

    RobertsonJFLindemannJPLlombart-CussacA. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ‘FIRST’ study. Breast Cancer Res Treat2012;136:503511.

    • Search Google Scholar
    • Export Citation
  • 50.

    MehtaRSBarlowWEAlbainKS. Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med2012;367:435444.

  • 51.

    BerghJJonssonPELidbrinkEK. FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. J Clin Oncol2012;30:19191925.

    • Search Google Scholar
    • Export Citation
  • 52.

    FryDWHarveyPJKellerPR. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther2004;3:14271438.

    • Search Google Scholar
    • Export Citation
  • 53.

    GillettCFantlVSmithR. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res1994;54:18121817.

    • Search Google Scholar
    • Export Citation
  • 54.

    YuQSicinskaEGengY. Requirement for CDK4 kinase function in breast cancer. Cancer Cell2006;9:2332.

  • 55.

    FinnRSDeringJConklinD. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res2009;11:R77.

    • Search Google Scholar
    • Export Citation
  • 56.

    FinnRSCrownJPLangI. Final results of a randomized Phase II study of PD 0332991 a cyclin-dependent kinase (CDK)-4/6 inhibitor in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18). Presented at: AACR Annual Meeting 2014; April5–92014; San Diego, California.

    • Search Google Scholar
    • Export Citation
  • 57.

    VallabhaneniSNairBCCortezV. Significance of ER-Src axis in hormonal therapy resistance. Breast Cancer Res Treat2011;130:377385.

  • 58.

    PaulDVukeljaSJHolmesFA. Letrozole plus dasatinib improves progression-free survival (PFS) in hormone receptor-positive, HER2- negative postmenopausal metastatic breast cancer (MBC) patients receiving first-line aromatase inhibitor therapy [abstract]. Cancer Res2013;73:Abstract S3-07.

    • Search Google Scholar
    • Export Citation
  • 59.

    ChiaSGradisharWMauriacL. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol2008;26:16641670.

    • Search Google Scholar
    • Export Citation
  • 60.

    CampbellRABhat-NakshatriPPatelNM. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. The J Biol Chem2001;276:98179824.

    • Search Google Scholar
    • Export Citation
  • 61.

    SimonciniTHafezi-MoghadamABrazilDP. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature2000;407:538541.

    • Search Google Scholar
    • Export Citation
  • 62.

    ChangSBMironPMironAIglehartJD. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells. J Surg Res2007;138:3744.

    • Search Google Scholar
    • Export Citation
  • 63.

    GhayadSEBiecheIVendrellJA. mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels. Cancer Sci2008;99:19922003.

    • Search Google Scholar
    • Export Citation
  • 64.

    PiccartMHortobagyiGNCamponeM. Everolimus plus exemestane for hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (BC): overall survival results from BOLERO-2. Ann Oncol2014;25:23572362.

    • Search Google Scholar
    • Export Citation
  • 65.

    PaplomataEZelnakAO'ReganR. Everolimus: side effect profile and management of toxicities in breast cancer. Breast Cancer Res Treat2013;140:453462.

    • Search Google Scholar
    • Export Citation
  • 66.

    BaselgaJCamponeMPiccartM. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med2012;366:520529.

    • Search Google Scholar
    • Export Citation
  • 67.

    BachelotTBourgierCCropetC. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol2012;30:27182724.

    • Search Google Scholar
    • Export Citation
  • 68.

    MassarwehSRomondEBlackEP. A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure. Breast Cancer Res Treat2014;143:325332.

    • Search Google Scholar
    • Export Citation
  • 69.

    SabnisGJGoloubevaOChumsriS. Functional activation of the estrogen receptor-alpha and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole. Cancer Res2011;71:18931903.

    • Search Google Scholar
    • Export Citation
  • 70.

    YardleyDAIsmail-KhanRRMelicharB. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J Clin Oncol2013;31:21282135.

    • Search Google Scholar
    • Export Citation
  • 71.

    WolffACLazarAABondarenkoI. Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol2013;31:195202.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 274 274 24
PDF Downloads 86 86 4
EPUB Downloads 0 0 0